BioCryst Pharmaceuticals (NASDAQ:BCRX) Given "Market Outperform" Rating at JMP Securities

JMP Securities reiterated their market outperform rating on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX - Free Report) in a research report released on Friday,Benzinga reports. JMP Securities currently has a $18.00 price target on the biotechnology company's stock.

Other equities research analysts have also issued research reports about the stock. Needham & Company LLC upped their price target on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a "buy" rating in a research report on Monday, January 13th. Barclays upped their price objective on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an "equal weight" rating in a research note on Tuesday, November 5th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. Finally, Evercore ISI increased their price target on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an "outperform" rating in a research note on Monday, January 13th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. Based on data from MarketBeat, BioCryst Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $15.50.

BioCryst Pharmaceuticals Stock Up 6.2 %

Shares of NASDAQ:BCRX traded up $0.47 on Friday, hitting $8.09. 2,356,338 shares of the company traded hands, compared to its average volume of 2,455,632. The stock has a 50 day simple moving average of $7.64 and a 200-day simple moving average of $7.69. The company has a market cap of $1.68 billion, a PE ratio of -13.26 and a beta of 1.75. BioCryst Pharmaceuticals has a 52 week low of $4.03 and a 52 week high of $8.88.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last released its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.07) EPS for the quarter, hitting the consensus estimate of ($0.07). The business had revenue of $117.10 million during the quarter, compared to the consensus estimate of $113.99 million. During the same quarter in the previous year, the business posted ($0.19) earnings per share. BioCryst Pharmaceuticals's quarterly revenue was up 35.1% compared to the same quarter last year. As a group, sell-side analysts anticipate that BioCryst Pharmaceuticals will post -0.38 earnings per share for the current year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. Counterweight Ventures LLC lifted its position in shares of BioCryst Pharmaceuticals by 591.7% during the third quarter. Counterweight Ventures LLC now owns 93,384 shares of the biotechnology company's stock valued at $710,000 after buying an additional 79,884 shares during the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of BioCryst Pharmaceuticals by 40.7% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 299,152 shares of the biotechnology company's stock valued at $2,274,000 after purchasing an additional 86,571 shares during the last quarter. Principal Financial Group Inc. boosted its position in shares of BioCryst Pharmaceuticals by 1,058.1% in the 3rd quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company's stock worth $3,127,000 after purchasing an additional 375,890 shares in the last quarter. Rice Hall James & Associates LLC grew its stake in shares of BioCryst Pharmaceuticals by 4.0% during the third quarter. Rice Hall James & Associates LLC now owns 2,163,743 shares of the biotechnology company's stock worth $16,444,000 after acquiring an additional 84,102 shares during the last quarter. Finally, Fisher Asset Management LLC grew its stake in shares of BioCryst Pharmaceuticals by 16.9% during the third quarter. Fisher Asset Management LLC now owns 3,338,062 shares of the biotechnology company's stock worth $25,369,000 after acquiring an additional 481,359 shares during the last quarter. 85.88% of the stock is currently owned by institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.